![](https://endpts.com/wp-content/uploads/2022/05/Nassim-Usman.jpg)
Nassim Usman, new Totus Medicines CEO
Totus Medicines closes $66M Series B to fund early-stage PI3Ka inhibitor, names new CEO
Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.